Treatment of Psoriatic Arthritis with Clinically Relevant Skin Psoriasis Involvement
When psoriatic arthritis is accompanied by substantial skin disease — either affecting a large proportion of body surface area or impacting the patient's quality of life — both components inform treatment selection from the outset.
Clinical Scenario
This protocol applies to psoriatic arthritis in the presence of clinically relevant skin psoriasis involvement: defined as body surface area involvement exceeding 10%, or skin disease that negatively impacts quality of life — such as involvement of the face or genitals, regardless of total area.
First-Line Treatment Approach
A conventional synthetic disease-modifying antirheumatic drug (csDMARD) is initiated promptly. In patients with clinically relevant skin involvement, one particular csDMARD is specifically preferred over the alternatives. The complete agent selection, sequencing criteria, and management algorithm are available in the full protocol.
Treatment Targets
A treat-to-target strategy is followed: at least 50% reduction in disease activity within 3 months, with the aim of reaching remission or low disease activity by 6 months. Therapy is adjusted if these milestones are not met.
References
DOI: 10.1136/ard-2024-225531
- Relevant skin involvement is defined as either extensive (body surface area involvement >10%), or as important to the patient, that is, impacting negatively their quality of life (such as is the case with face or genital involvement).
- With clinically relevant skin involvement, preference should be given to an IL-17A or IL-17A/F or IL-23 or IL-12/23 inhibitor.
- In patients with polyarthritis, or those with monoarthritis/oligoarthritis and poor prognostic factors (eg, structural damage, elevated acute phase reactants, dactylitis or nail involvement), a csDMARD should be initiated rapidly, with methotrexate preferred in those with clinically relevant skin involvement.
- Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.
- Since the EULAR recommendations adhere to a treat-to-target (T2T) approach which implies a reduction of disease activity by at least 50% within 3 months and reaching the treatment target within 6 months, a csDMARD should not be continued if these therapeutic goals are not attained.